{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:31:53Z","timestamp":1786984313428,"version":"build-2736575974"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.anai.2019.07.004","type":"journal-article","created":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T19:13:29Z","timestamp":1562613209000},"page":"232-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps"],"prefix":"10.1016","volume":"123","author":[{"given":"Christopher D.","family":"Codispoti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboobeh","family":"Mahdavinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2019.07.004_bib1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/000348941112000701","article-title":"Incremental health care utilization and expenditures for chronic rhinosinusitis in the United States","volume":"120","author":"Bhattacharyya","year":"2011","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.anai.2019.07.004_bib2","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/lary.24630","article-title":"Productivity costs in patients with refractory chronic rhinosinusitis","volume":"124","author":"Rudmik","year":"2014","journal-title":"Laryngoscope"},{"key":"10.1016\/j.anai.2019.07.004_bib3","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.jaci.2015.10.012","article-title":"Patient-reported outcome measures for adult chronic rhinosinusitis: a systematic review and quality assessment","volume":"136","author":"Rudmik","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.07.004_bib4","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.jaci.2015.08.037","article-title":"Direct costs of adult chronic rhinosinusitis by using 4 methods of estimation: results of the US Medical Expenditure Panel Survey","volume":"136","author":"Caulley","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.07.004_bib5","first-page":"3","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2012","volume":"23","author":"Fokkens","year":"2012","journal-title":"Rhinol Suppl"},{"key":"10.1016\/j.anai.2019.07.004_bib6","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1002\/lary.20653","article-title":"Long-term outcomes from the English national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis","volume":"119","author":"Hopkins","year":"2009","journal-title":"Laryngoscope"},{"key":"10.1016\/j.anai.2019.07.004_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/lary.26741","article-title":"Revision rates and time to revision following endoscopic sinus surgery: a large database analysis","volume":"128","author":"Stein","year":"2018","journal-title":"Laryngoscope"},{"key":"10.1016\/j.anai.2019.07.004_bib8","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1164\/rccm.201412-2278OC","article-title":"Cytokines in chronic rhinosinusitis. role in eosinophilia and aspirin-exacerbated respiratory disease","volume":"192","author":"Stevens","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2019.07.004_bib9","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jaci.2014.08.031","article-title":"Increased noneosinophilic nasal polyps in chronic rhinosinusitis in US second-generation Asians suggest genetic regulation of eosinophilia","volume":"135","author":"Mahdavinia","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.07.004_bib10","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.07.004_bib11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.07.004_bib12","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.anai.2019.07.004_bib13","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.anai.2019.07.004_bib14","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2019.07.004_bib15","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2019.07.004_bib16","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.anai.2019.07.004_bib17","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.07.004_bib18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4193\/Rhino09.144","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis","volume":"48","author":"Pinto","year":"2010","journal-title":"Rhinology"},{"key":"10.1016\/j.anai.2019.07.004_bib19","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.07.004_bib20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.07.004_bib21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.anai.2019.07.004_bib22","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.07.004_bib23","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/lary.25180","article-title":"Cost of adult chronic rhinosinusitis: a systematic review","volume":"125","author":"Smith","year":"2015","journal-title":"Laryngoscope"},{"key":"10.1016\/j.anai.2019.07.004_bib24","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"key":"10.1016\/j.anai.2019.07.004_bib25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","article-title":"The estimation of a preference-based measure of health from the SF-36","volume":"21","author":"Brazier","year":"2002","journal-title":"J\u00a0Health Econ"},{"key":"10.1016\/j.anai.2019.07.004_bib26","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/alr.21588","article-title":"Health utility outcomes in patients undergoing medical management for chronic rhinosinusitis: a prospective multiinstitutional study","volume":"5","author":"Luk","year":"2015","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.anai.2019.07.004_bib27","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1749-4486.2006.01275.x","article-title":"The national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis","volume":"31","author":"Hopkins","year":"2006","journal-title":"Clin Otolaryngol"},{"key":"10.1016\/j.anai.2019.07.004_bib28","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/lary.25108","article-title":"Using preoperative SNOT-22 score to inform patient decision for Endoscopic sinus surgery","volume":"125","author":"Rudmik","year":"2015","journal-title":"Laryngoscope"},{"key":"10.1016\/j.anai.2019.07.004_bib29","series-title":"Cost-effectiveness in Health and Medicine","author":"Neumann","year":"2017"},{"key":"10.1016\/j.anai.2019.07.004_bib30","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.anai.2019.07.004_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/lary.24916","article-title":"Economic evaluation of endoscopic sinus surgery versus continued medical therapy for refractory chronic rhinosinusitis","volume":"125","author":"Rudmik","year":"2015","journal-title":"Laryngoscope"},{"key":"10.1016\/j.anai.2019.07.004_bib32","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/alr.21697","article-title":"Cost utility analysis of endoscopic sinus surgery for chronic rhinosinusitis","volume":"6","author":"Scangas","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.anai.2019.07.004_bib33","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/lary.26391","article-title":"Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis","volume":"127","author":"DeConde","year":"2017","journal-title":"Laryngoscope"},{"key":"10.1016\/j.anai.2019.07.004_bib34","article-title":"Long-term outcomes of endoscopic sinus surgery in the management of adult chronic rhinosinusitis","author":"Smith","year":"2019","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.anai.2019.07.004_bib35","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.anai.2014.07.025","article-title":"Diagnosis and management of rhinosinusitis: a practice parameter update","volume":"113","author":"Peters","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2019.07.004_bib36","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.jaci.2013.02.036","article-title":"Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology","volume":"131","author":"Akdis","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.07.004_bib37","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jaip.2016.05.004","article-title":"Phenotypes and emerging endotypes of chronic rhinosinusitis","volume":"4","author":"Bachert","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2019.07.004_bib38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jaci.2016.06.063","article-title":"Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois","volume":"139","author":"Tan","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.07.004_bib39","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.jaci.2008.02.018","article-title":"T-cell regulation in chronic paranasal sinus disease","volume":"121","author":"Van Bruaene","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.07.004_bib40","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2016.05.041","article-title":"Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania","volume":"138","author":"Wang","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.07.004_bib41","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.jaci.2013.12.1092","article-title":"Basophils are elevated in nasal polyps of patients with chronic rhinosinusitis without aspirin sensitivity","volume":"133","author":"Mahdavinia","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.07.004_bib42","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/iid3.161","article-title":"Group 2 innate lymphoid cells are elevated and activated in chronic rhinosinusitis with nasal polyps","volume":"5","author":"Poposki","year":"2017","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.anai.2019.07.004_bib43","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jaip.2017.04.038","article-title":"Biologic therapy and novel molecular targets of severe asthma","volume":"5","author":"Pepper","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2019.07.004_bib44","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/intimm\/dxp102","article-title":"IL-5- and eosinophil-mediated inflammation: from discovery to therapy","volume":"21","author":"Kouro","year":"2009","journal-title":"Int Immunol"},{"key":"10.1016\/j.anai.2019.07.004_bib45","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.07.004_bib46","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.151.5.2623","article-title":"Humanization of an antibody directed against IgE","volume":"151","author":"Presta","year":"1993","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.anai.2019.07.004_bib47","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.anai.2019.07.004_bib48","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4193\/Rhin17.139","article-title":"Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study","volume":"56","author":"Bidder","year":"2018","journal-title":"Rhinology"},{"key":"10.1016\/j.anai.2019.07.004_bib49","series-title":"FDA Approved Drug Products","year":"2019"},{"key":"10.1016\/j.anai.2019.07.004_bib50","series-title":"FDA Approved Drug Products","year":"2019"},{"key":"10.1016\/j.anai.2019.07.004_bib51","series-title":"FDA Approved Drug Products","year":"2019"},{"key":"10.1016\/j.anai.2019.07.004_bib52","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.anai.2019.01.018","article-title":"Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: ro biologic or not to biologic?","volume":"122","author":"Anderson","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2019.07.004_bib53","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.anai.2019.07.004_bib54","series-title":"FDA Approves First Treatment for Chronic Rhinosinusitis With Nasal Polyps","year":"2019"},{"key":"10.1016\/j.anai.2019.07.004_bib55","first-page":"CD006991","article-title":"Surgical versus medical interventions for chronic rhinosinusitis with nasal polyps","volume":"12","author":"Rimmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.anai.2019.07.004_bib56","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1002\/lary.21446","article-title":"Complications in endoscopic sinus surgery for chronic rhinosinusitis: a 25-year experience","volume":"121","author":"Stankiewicz","year":"2011","journal-title":"Laryngoscope"},{"key":"10.1016\/j.anai.2019.07.004_bib57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.anai.2019.06.012","article-title":"Mepolizumab utility in successful aspirin desensitizatin in aspirin-exacerbated respiratory disease in a refractory case","volume":"123","author":"Mahdavinia","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2019.07.004_bib58","doi-asserted-by":"crossref","first-page":"e0127228","DOI":"10.1371\/journal.pone.0127228","article-title":"Airway inflammation in chronic rhinosinusitis with nasal polyps and asthma: the united airways concept further supported","volume":"10","author":"Hakansson","year":"2015","journal-title":"PLoS One"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619305009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619305009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:22:20Z","timestamp":1761052940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120619305009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1081120619305009"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2019.07.004","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736219573.793565973","asserted-by":"object"}]},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2019.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}